These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 17502466)

  • 21. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial.
    Poewe WH; Rascol O; Quinn N; Tolosa E; Oertel WH; Martignoni E; Rupp M; Boroojerdi B;
    Lancet Neurol; 2007 Jun; 6(6):513-20. PubMed ID: 17509486
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of 6-month earlier versus postponed initiation of rotigotine on long-term outcome: post hoc analysis of patients with early Parkinson's disease with mild symptom severity.
    Timmermann L; Asgharnejad M; Boroojerdi B; Dohin E; Woltering F; Elmer LW
    Expert Opin Pharmacother; 2015; 16(10):1423-33. PubMed ID: 25997442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Randomized Controlled Exploratory Pilot Study to Evaluate the Effect of Rotigotine Transdermal Patch on Parkinson's Disease-Associated Chronic Pain.
    Rascol O; Zesiewicz T; Chaudhuri KR; Asgharnejad M; Surmann E; Dohin E; Nilius S; Bauer L
    J Clin Pharmacol; 2016 Jul; 56(7):852-61. PubMed ID: 26626320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rotigotine: transdermal dopamine agonist treatment of Parkinson's disease and restless legs syndrome.
    Splinter MY
    Ann Pharmacother; 2007 Feb; 41(2):285-95. PubMed ID: 17213296
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of Rotigotine at Different Stages of Parkinson's Disease Symptom Severity and Disability: A Post Hoc Analysis According to Baseline Hoehn and Yahr Stage.
    Giladi N; Nicholas AP; Asgharnejad M; Dohin E; Woltering F; Bauer L; Poewe W
    J Parkinsons Dis; 2016 Oct; 6(4):741-749. PubMed ID: 27567886
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rotigotine vs ropinirole in advanced stage Parkinson's disease: a double-blind study.
    Mizuno Y; Nomoto M; Hasegawa K; Hattori N; Kondo T; Murata M; Takeuchi M; Takahashi M; Tomida T;
    Parkinsonism Relat Disord; 2014 Dec; 20(12):1388-93. PubMed ID: 25455692
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High doses of rotigotine transdermal patch: results of an open-label, dose-escalation trial in patients with advanced-stage, idiopathic Parkinson disease.
    Rektor I; Babic T; Boothmann B; Polivka J; Boroojerdi B; Randerath O
    Clin Neuropharmacol; 2009; 32(4):193-8. PubMed ID: 19644228
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson's disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER.
    LeWitt PA; Boroojerdi B; Surmann E; Poewe W; ;
    J Neural Transm (Vienna); 2013 Jul; 120(7):1069-81. PubMed ID: 23208198
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER).
    Trenkwalder C; Kies B; Rudzinska M; Fine J; Nikl J; Honczarenko K; Dioszeghy P; Hill D; Anderson T; Myllyla V; Kassubek J; Steiger M; Zucconi M; Tolosa E; Poewe W; Surmann E; Whitesides J; Boroojerdi B; Chaudhuri KR;
    Mov Disord; 2011 Jan; 26(1):90-9. PubMed ID: 21322021
    [TBL] [Abstract][Full Text] [Related]  

  • 30. One year open-label safety and efficacy trial with rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome.
    Oertel WH; Benes H; Garcia-Borreguero D; Geisler P; Högl B; Trenkwalder C; Tacken I; Schollmayer E; Kohnen R; Stiasny-Kolster K;
    Sleep Med; 2008 Dec; 9(8):865-73. PubMed ID: 18753003
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rotigotine and specific non-motor symptoms of Parkinson's disease: post hoc analysis of RECOVER.
    Ray Chaudhuri K; Martinez-Martin P; Antonini A; Brown RG; Friedman JH; Onofrj M; Surmann E; Ghys L; Trenkwalder C
    Parkinsonism Relat Disord; 2013 Jul; 19(7):660-5. PubMed ID: 23557594
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rotigotine transdermal patch in combination therapy for Parkinson's disease--observations in routine clinical practice.
    Ceballos-Baumann A; Häck HJ
    Curr Med Res Opin; 2011 Oct; 27(10):1899-905. PubMed ID: 21867400
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of rotigotine in elderly patients with Parkinson's disease in comparison with the non-elderly: a post hoc analysis of randomized, double-blind, placebo-controlled trials.
    Nomoto M; Iwaki H; Kondo H; Sakurai M
    J Neurol; 2018 Feb; 265(2):253-265. PubMed ID: 29164312
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rotigotine transdermal patch in Chinese patients with advanced Parkinson's disease: A randomized, double-blind, placebo-controlled pivotal study.
    Zhang ZX; Liu CF; Tao EX; Shao M; Liu YM; Wang J; Asgharnejad M; Xue HB; Surmann E; Bauer L
    Parkinsonism Relat Disord; 2017 Nov; 44():6-12. PubMed ID: 28827011
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome: a randomized, placebo-controlled polysomnographic study.
    Oertel WH; Benes H; Garcia-Borreguero D; Högl B; Poewe W; Montagna P; Ferini-Strambi L; Sixel-Döring F; Trenkwalder C; Partinen M; Saletu B; Polo O; Fichtner A; Schollmayer E; Kohnen R; Cassel W; Penzel T; Stiasny-Kolster K
    Sleep Med; 2010 Oct; 11(9):848-56. PubMed ID: 20813583
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The safety and tolerability of rotigotine transdermal system over a 6-year period in patients with early-stage Parkinson's disease.
    Giladi N; Boroojerdi B; Surmann E
    J Neural Transm (Vienna); 2013 Sep; 120(9):1321-9. PubMed ID: 23508526
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rotigotine transdermal system and evaluation of pain in patients with Parkinson's disease: a post hoc analysis of the RECOVER study.
    Kassubek J; Chaudhuri KR; Zesiewicz T; Surmann E; Boroojerdi B; Moran K; Ghys L; Trenkwalder C
    BMC Neurol; 2014 Mar; 14():42. PubMed ID: 24602411
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rotigotine Transdermal Patch Does Not Make Parkinson Disease Patients Sleepy During Daytime.
    Ohta K; Osada T
    Clin Neuropharmacol; 2015; 38(6):231-5. PubMed ID: 26536020
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of long-term treatment with rotigotine transdermal system on dyskinesia in patients with early-stage Parkinson's disease.
    Giladi N; Ghys L; Surmann E; Boroojerdi B; Jankovic J
    Parkinsonism Relat Disord; 2014 Dec; 20(12):1345-51. PubMed ID: 25444083
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rotigotine for nocturnal hypokinesia in Parkinson's disease: Quantitative analysis of efficacy from a randomized, placebo-controlled trial using an axial inertial sensor.
    Bhidayasiri R; Sringean J; Chaiwong S; Anan C; Penkeaw N; Leaknok A; Boonpang K; Saksornchai K; Rattanachaisit W; Thanawattano C; Jagota P
    Parkinsonism Relat Disord; 2017 Nov; 44():124-128. PubMed ID: 28818560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.